• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » First Non-Drug Treatment Approved by FDA for Treating Children With ADHD

First Non-Drug Treatment Approved by FDA for Treating Children With ADHD

June 11, 2019
Talia Puzantian, PharmD, BCPP and Joshua Feder, MD
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Talia Puzantian, PharmD, BCPP Joshua Feder, MD Drs. Puzantian and Feder have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.
NeuroSigma made a splash by announcing that the FDA has granted medical device approval for its external Monarch Trigeminal Nerve Stimulation (eTNS) System for treating kids with ADHD ages 7–12 who are not currently taking medications.

What does medical device approval mean?
The FDA reviewed the Monarch eTNS System through the de novo ­pre-market review pathway, a less rigorous process than the usual pre-marketing approval process. This is a regulatory pathway for low- to moderate-risk devices of a new type, which asserts that the device is safe to use. The process does not affirm effectiveness of the device for the intended use. This level of approval means that subsequent devices of the same type with the same intended use may go through a process that allows the manufacturer to market its device just by demonstrating equivalence to this first (de novo) device.

How does it work?
The cellphone-sized device is meant to be used at home, under a caregiver’s supervision, for 8 hours while the child sleeps. The device has a thin wire that connects to a small adhesive electrode patch, which is placed on the child’s forehead just above the eyebrows. It provides a low-level electrical pulse (120 Hz frequency and cycles of 30 seconds on/off with 2–4 milli-amperes of current), causing mild stimulation to branches of the trigeminal nerve.

Is it effective?
A small 4-week study of kids with moderate to severe ADHD compared treatment with eTNS (n = 32) to a sham placebo device (n = 30). The primary outcome measured was the clinician-administered ADHD Rating Scale ­(ADHD-RS) total score. Although only slightly more than half of eTNS kids had clinically meaningful improvement, a statistically significant reduction was seen compared to placebo (eTNS score 34.1 at baseline to 23.4 at 4 weeks vs placebo device score 33.7 at baseline to 27.5 at 4 weeks), though improvement was seen in both groups. The estimated effect size of 0.5 is similar to the effect sizes seen with non-stimulant medications used to treat ADHD (a medium effect). The number-needed-to-treat (NNT) based on Clinical Global Impression—Improvement (CGI-I) scores at week 4 was 3. This means 3 people would need to be treated to find one who responds (in other words, for every patient who does better than placebo, 2 would have done just as well on ­placebo).

Is it safe?
Most kids will feel a tingling sensation on the skin. Drowsiness, increased appetite, trouble sleeping, teeth clenching, headache, and fatigue were the side effects most commonly reported in the study. A statistically significant increase in heart rate was seen, but pulse rates were still in the normal range and kids were not symptomatic. Weight gain was also statistically significantly greater in the eTNS group. Skin whitening or discoloration under the patch was seen in both groups, particularly in darker-skinned kids. This was attributed to loss of superficial skin layers when the patch was removed, and the discoloration resolved over time and with sun exposure.

How much will it cost?
The prescription-only device will be available from NeuroSigma “in the coming months,” and pricing information is not yet available, although some accounts have priced starter kits at $900.

CCPR’s Take
This is an interesting “gee whiz” device that will no doubt capture the imagination of families looking for a simple approach who don’t want their kids treated with medications, cognitive behavioral therapy (CBT), or parent training, even though these have a proven track record of safety and efficacy. We’re going to need more data than 62 kids in a 4-week manufacturer-run study to understand eTNS’ place in therapy for kids with ADHD. Moreover, the weight gain seen in this study begs for more investigation, perhaps having to do with changes in sleep and cortisol.
Child Psychiatry
KEYWORDS adhd adolescents attention-deficit-hyperactivity-disorder brain_devices child_psychiatry children efficacy etns news_of_note pediatric safety teens treatment trigeminal-nerve-stimulation
Puzantian 150x150
Talia Puzantian, PharmD, BCPP

Treating Alcohol Use Disorder—A Fact Book (2023)

More from this author
Eic photo joshua d feder md jpg 150x150
Joshua Feder, MD

Assessment of Non-Suicidal Self-Injury in Children and Adolescents

More from this author
www.thecarlatreport.com
Issue Date: June 11, 2019
SUBSCRIBE NOW
Table Of Contents
Note From the Editor-in-Chief
Medications for Depression
Practical Approaches to Vetting Clinical Research
FDA Approves Adhansia XR
First Non-Drug Treatment Approved by FDA for Treating Children With ADHD
Prescribing Patterns for Children With Anxiety Disorders
Melatonin for Insomnia in Patients With Autism
Steroid-Induced Psychosis in the ­Pediatric Population
Risk of Psychosis With Stimulants in ADHD Patients
Transcranial Magnetic Stimulation (TMS) for Depression in Children and Adolescents
CME Post-Test - Depression in Children and Adolescents, CCPR, Summer 2019
DOWNLOAD NOW
Featured Book
  • CMFB2e_Cover.png

    Child Medication Fact Book for Psychiatric Practice, Second Edition (2023)

    All the important facts covering child and adolescent psychopharmacology.
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • teen_depression.jpeg
    Child Psychiatry

    Assessment of Non-Suicidal Self-Injury in Children and Adolescents

    Learn how to assess and intervene with NSSI, including ideas for supporting autonomy while addressing the behavior.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.